Page 2 - லீ மருந்துகள் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Share this article Share this article ResearchAndMarkets.com s offering. By the end of 2020, the number of diabetic patients in China has exceeded 1.13 billion. For patients with type 1 diabetes, insulin is the only effective treatment. In addition, 30% to 40% of patients with type 2 diabetes will eventually become insulin-dependent. With the increase in the number of diabetic patients, the market size of diabetes treatment drugs in China is also rising, among which third-generation insulins such as insulin glargine, insulin aspart, and lispro insulin occupy a relatively high market share. Recombinant insulin lispro is a new type of insulin analogue with fast onset and shorter duration of action, which is more in line with the insulin secretion curve of physiological meals. Its preparation is recombinant insulin lispro injection, protamine zinc recombinant insulin lispro Mixed injection (25R) and protamine zinc recombinant insulin lispro mixed injection (50R) which can better co

Lilly humalogEli lillyLaura woodDevelopment of china recombinant lispro insulin marketDevelopment of recombinant lispro insulinGan lee pharmaceuticalsOffice hours callGan lee pharmaceuticals prandilinGanli pharmaceutical co ltdE st office hours callTonghua dongbao pharmaceutical co ltdRecombinant lispro insulin marketRecombinant lispro insulin injectionHumalog mixRecombinant insulin glargine injectionLispro insulin